Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Document › Details

4SC AG. (2/23/11). "Press Release: 4SC Announces Capital Increase". Planegg-Martinsried.

Region Region Germany
Organisations Organisation 4SC AG (FSE: VSC)
  Group 4SC (Group)
  Organisation 2 Kempen & Co. N.V.
  Group Van Lanschot (Group)
Products Product vidofludimus (4SC-101)
  Product 2 investment banking
     


The management board of 4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, decided today with the supervisory board's consent to make partial use of the authorised capital to increase the Company's share capital from 38,502,739 shares to up to 42,353,011 shares by issuing up to 3,850,272 new, no-par value bearer shares, each with a notional interest of EUR 1.00 in the share capital. The new shares will be offered to institutional investors as part of an accelerated book-building process, excluding the subscription rights of the existing shareholders.

Kempen & Co. is acting as Lead Manager and Donner & Reuschel Privatbank is acting as the Listing Agent for the transaction.


- End of Ad-hoc Notification -


About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in Phase II development in rheumatoid arthritis and inflammatory bowel disease (IBD), for which positive results from a Phase IIa study were recently reported. The company's lead oncology compound, resminostat (4SC-201), a pan-histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma, Hodgkin's lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information, please visit www.4sc.com.

Disclaimer

This publication may contain projections or estimates relating to plans and objectives relating to future operations, products, or services, future financial results or assumptions underlying or relating to any such statements. These forward looking statements are subject to risks and uncertainties, which cannot be foreseen and which are beyond the control of 4SC AG. Many factors can cause actual results to differ materially from any estimates expressed or implied by this publication. 4SC AG has no obligation to periodically update or release any revisions to the forward-looking statements contained in this publication to reflect events or circumstances after the date of this release.

This publication constitutes neither an offer to sell nor a solicitation to buy securities of 4SC AG. The shares of 4SC AG may only be offered or sold in the United States after registration or without registration under an exemption from the registration requirements of the U.S. Securities Act of 1933, as 4SC AG has no obligation to periodically update or release any revisions to the forward-looking statements contained in this release to
reflect events or circumstances after the date of this release. Shares have not been and will not be registered under the Securities Act. 4SC AG intends no public offering of the shares in the United States.

For more information please contact:

4SC AG
Yvonne Alexander, IR & PR
Tel.: +49 (0) 89 70 07 63 66

MC Services (Europe)
Raimund Gabriel
Tel.: +49 (0) 89 21 02 28 30

The Trout Group (USA)
Chad Rubin
Tel.: +1 646 378 2947

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for 4SC (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top